ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2266 • 2016 ACR/ARHP Annual Meeting

    A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout

    Ronald Berenson1, Maura-Ann Matthews1, Wayne Wallis2, Raj Dua1, Margaret Moore1, Robert Terkeltaub3 and Christopher Clegg1,4, 1Aequus BioPharma, Inc., Seattle, WA, 2Dyad Life Sciences, LLC, Seattle, WA, 3Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, 4TRIA Bioscience, Seattle, WA

    Background/Purpose: The melanocortins (MCs) are endogenous peptides (including ACTH, α-MSH and γ-MSH), which bind 5 G protein-coupled receptors (MCRs 1 through 5) with varying affinity.…
  • Abstract Number: 2267 • 2016 ACR/ARHP Annual Meeting

    AMP-Activated Protein Kinase: A  Target for Methotrexate in Macrophages

    Cornelia Cudrici1, Martin Pelletier2 and Richard M. Siegel3, 1NIAMS, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, 2Infectious and immune diseases Centre Hospitalier de l'Université Laval (CHUL) Québec, Québec, QC, Canada, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD

    Background/Purpose: Methotrexate (MTX) remains a cornerstone of treatment in multiple forms of inflammatory arthritis, lupus and vasculitis. The anti-inflammatory effects of MTX are more likely…
  • Abstract Number: 2268 • 2016 ACR/ARHP Annual Meeting

    Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity

    Xihua Cao1, Jeffrey N. Miner2, Robert Terkeltaub3,4 and Ru Liu-Bryan1,4, 1VA Medical Center, San Diego, CA, 2Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, 3Rheumatology, VA Medical Center, San Diego, CA, 4Medicine-Rheumatology, University of California, San Diego, La Jolla, CA

    Background/Purpose: High dietary content of fructose (in table sugar, sweetened sodas, energy beverages, and fruit juices) is a substantial risk factor for both hyperuricemia and…
  • Abstract Number: 2269 • 2016 ACR/ARHP Annual Meeting

    Proteinaceous Amorphous Calcium Carbonates As a Novel Family of Crystals in Synovial Fluid from Symptomatic Joints

    Bolan Li1, Nora Singer2,3 and Ozan Akkus3,4, 1Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, 2Medicine and Pediatrics, MetroHealth System, Cleveland, OH, 3Case Western Reserve University School of Medicine, Cleveland, OH, 4University Hospitals Case Medical Center, Cleveland, OH

    Background/Purpose: There are many types of particulate matter in synovial fluid, and specific identification of these particles are challenging. We assessed synovial fluid samples from…
  • Abstract Number: 2270 • 2016 ACR/ARHP Annual Meeting

    Inflammasome/IL-1β Activation Induced By Calcium Pyrophosphate Dihydrate Crystals Is Mainly Driven By a P2X7 Receptor-Independent Potassium Efflux

    Laure Campillo-Gimenez1, Félix Renaudin2, Pierre Bobé3, Marjolaine Gosset4, Christèle Combes5, Martine Cohen-Solal2,6, Frederic Lioté2,6 and Hang-Korng Ea2,6, 1Hôpital Lariboisière, Centre Viggo Petersen, INSERM UMR1132, Paris Diderot University, Paris, France, 2INSERM UMR1132, Paris Diderot University, Paris, France, 3INSERM UMRS757, Paris Sud University, Orsay, France, 4EA2496, Paris Descartes University, Montrouge, France, 5ENSIACET, CIRIMAT, INPT-UPS-CNRS, Toulouse, France, 6AP-HP, Lariboisière Hospital, Rheumatology Department, Paris, France

    Background/Purpose: Calcium pyrophosphate crystals including monoclinic and triclinic dihydrate phases (m- and t-CPPD) are found in 40% of end-stage osteoarthritis (OA) patients. Frequently asymptomatic, it…
  • Abstract Number: 2271 • 2016 ACR/ARHP Annual Meeting

    Mutation in Osteoprotegerin Gene: Early-Onset Osteoarthritis and Chondrocalcinosis in a US Family of Italian/German Ancestry

    Urooj Qazi1, Charlene J. Williams2, Mark L. Bernstein3, Aaron Charniak4, Amaryllis Ortiz2, Ann K. Rosenthal5, Lucien Cardinal1 and Alan T. Kaell1, 1Internal Medicine, SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Port Jefferson, NY, 2Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, 3Rheumatology, SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Stony Brook, NY, 4SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Port Jefferson, NY, 5Division of Rheumatology, Medical College of WI, Milwaukee, WI

    Background/Purpose: Chondrocalcinosis is characterized by calcium pyrophosphate dihydrate (CPPD) deposition in articular cartilage. It can occur as a rare autosomal dominant disorder with florid early-onset…
  • Abstract Number: 2272 • 2016 ACR/ARHP Annual Meeting

    The Influence of Genetic Variants on Renal Uric Acid Excretion in Response to Frusemide

    Nicola Dalbeth1, Jordyn de Kwant1, Gregory Gamble2, Amanda Phipps-Green3, Anne Horne2, Robert Doughty1, Lisa K. Stamp4 and Tony R. Merriman5, 1University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3University of Otago, Dunedin, New Zealand, 4University of Otago, Christchurch, New Zealand, 5Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

    Background/Purpose: Diuretic use is strongly associated with development of hyperuricaemia and gout.  Genetic variation in the renal uric acid transporters SLC2A9 (encoding GLUT9) and SLC22A11…
  • Abstract Number: 2273 • 2016 ACR/ARHP Annual Meeting

    Trans-Ancestral Meta-Analysis Identifies Nine New Loci Associated with Serum Uric Acid Concentrations

    James Boocock1, Eli A. Stahl2, David B. Mount3, Tony R. Merriman4, Hyon K. Choi5, Yukinori Okada6, Murray Cadzow1 and Ruth Topless1, 1University of Otago, Dunedin, New Zealand, 2Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, 3Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 5Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 6Osaka University, Osaka, Japan

      Background/Purpose: Serum uric acid is an important biomarker for gout disease and kidney function. Genome-wide association study (GWAS) meta-analyses have identified 28 loci in…
  • Abstract Number: 2274 • 2016 ACR/ARHP Annual Meeting

    Evidence of Phospho-Degron Regulating Expression of Urate Secretory Transporter ABCG2

    Alexis Hofherr1, Meng Li2, Michael Kottgen1 and Owen M. Woodward2, 1Nephrology, University of Freiburg Medical Center, Freiburg, Germany, 2Physiology, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose:  ABCG2 is a high capacity urate secretory transporter of the renal proximal tubule. The common Q141K ABCG2 mutation causes gout in humans through an…
  • Abstract Number: 2275 • 2016 ACR/ARHP Annual Meeting

    Genome-Wide Association Study of Gout in New Zealand Polynesian People

    Tanya Flynn1, Ruth Topless1, Murray Cadzow1, Amanda Phipps-Green1, Nick Burns1, Nicola Dalbeth2, Lisa K. Stamp3, Jennie Harre Hindmarsh4 and Tony R. Merriman5, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Christchurch, New Zealand, 4Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, 5Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

    Background/Purpose: The prevalence of gout in New Zealand Polynesian (Māori and Pacific) populations is approximately twice that of the New Zealand European population, with a…
  • Abstract Number: 2276 • 2016 ACR/ARHP Annual Meeting

    Pleiotropic Effect of ABCG2 in Gout

    Tony R. Merriman1, Amanda Phipps-Green2, James Boocock2, Philip Riches3, Anne-Kathrin Tausche4, Timothy Radstake5, Matthijs Janssen6, Leo .A.B. Joosten7, Tim L Jansen8, Alexander So9, Jennie Harre Hindmarsh10, Lisa K. Stamp11, Nicola Dalbeth12 and Rebekah Wrigley2, 1Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3University of Edinburgh, Edinburgh, United Kingdom, 4Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, 5Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 6Department of Rheumatology, Rijnstate Hospital Arnhem, Arnhem, Netherlands, 7Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 8Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 9Rheumatology Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland, 10Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, 11University of Otago, Christchurch, New Zealand, 12University of Auckland, Auckland, New Zealand

    Background/Purpose: The ABCG2 Q141K (rs2231142) variant is an established cause of hyperuricaemia in Europeans. Although the effect size of ABCG2 rs2231142 on serum urate levels…
  • Abstract Number: 2277 • 2016 ACR/ARHP Annual Meeting

    Exon Sequencing Reveals a Significant Burden of Non-Synonymous Variants in Both SLC22A11 (OAT4) and SLC22A12 (URAT1) in European Hyperuricemic Individuals

    Tanya Flynn1, James Boocock1, Murray Cadzow1, Ruth Topless1, Amanda Phipps-Green1, Nicola Dalbeth2, Lisa K. Stamp3, David B. Mount4, Asim Mandal4, Hyon K. Choi5, Eli A. Stahl6 and Tony R. Merriman7, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Christchurch, New Zealand, 4Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 6Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, 7Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

    Background/Purpose: Common variants within the uric acid transporter genes SLC22A11 (OAT4) and SLC22A12 (URAT1) have been associated with hyperuricaemia and gout in multiple populations, but…
  • Abstract Number: 2278 • 2016 ACR/ARHP Annual Meeting

    Precision of Gout Definitions for Population-Based Genetic Studies: Analysis of the UK Biobank

    Murray Cadzow1, Tony R. Merriman2 and Nicola Dalbeth3, 1University of Otago, Dunedin, New Zealand, 2Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 3University of Auckland, Auckland, New Zealand

    Background/Purpose : Accurate case-definition is important for epidemiological studies of gout. However, in multipurpose cohort studies frequently used for genome wide association studies, limited information…
  • Abstract Number: 2279 • 2016 ACR/ARHP Annual Meeting

    Soluble Urate: A Direct Mediator of Bone Turnover?

    Nicola Dalbeth1, Bregina Pool2, Ashika Chhana3, Jian-Ming Lin1, Mei-Lin Tay1, Paul Tan1, Karen E. Callon1, Dorit Naot3 and Jillian Cornish2, 1University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3Medicine, University of Auckland, Auckland, New Zealand

    Background/Purpose: Observational studies have reported that hyperuricemia may be protective in the development of osteoporosis.  Serum urate concentrations positively correlate with bone density, and higher…
  • Abstract Number: 2280 • 2016 ACR/ARHP Annual Meeting

    Monosodium Urate Crystal-Induced Inflammation Promotes Osteocyte Expression of Pro-Resorptive and Inflammatory Mediators: Implications for Erosive Gout

    Ashika Chhana1, Mei-Lin Tay2, Bregina Pool3, Karen E. Callon2, David Musson2, Dorit Naot1, Gregory Gamble3, Jillian Cornish3 and Nicola Dalbeth2, 1Medicine, University of Auckland, Auckland, New Zealand, 2University of Auckland, Auckland, New Zealand, 3Department of Medicine, University of Auckland, Auckland, New Zealand

    Background/Purpose:   Bone erosion in gout is strongly associated with tophi; lesions comprising of inflammatory cells surrounding collections of monosodium urate (MSU) crystals.  Osteocytes are…
  • « Previous Page
  • 1
  • …
  • 1748
  • 1749
  • 1750
  • 1751
  • 1752
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology